This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saleem, A. Articles by Aboagye, E. O. Search for Related Content PubMed PubMed Citation Articles by Saleem, A. Articles by Aboagye, E. O.

Pharmacokinetic Evaluation of N-[2-(Dimethylamino)Ethyl]Acridine-4-Carboxamide in Patients by Positron Emission Tomography

From the Cancer Research Campaign Positron Emission Tomography Oncology Group, Methodology Group, and Chemistry and Engineering Group, Division of Cancer Medicine, Imperial College School of Medicine, Medical Research Council Cyclotron Unit, Hammersmith Hospital; School of Pharmacy, University of London, London; and Department of Oncology, Addenbrookes Hospital, Cambridge, United Kingdom.

Address reprint requests to Pat M. Price, MD, Cancer Research Campaign Positron Emission Tomography Oncology Group, Division of Cancer Medicine, Imperial College School of Medicine, Medical Research Council Cyclotron Unit, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom; email: anne.mason{at}christie-tr.nwest.nhs.uk © 2001 by American Society of Clinical Oncology. 0732-183X/01/05-2

PURPOSE: To evaluate tumor, normal tissue, and plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). The study aimed to determine the pharmacokinetics of carbon-11–labeled DACA ([¹¹C]DACA) and evaluate the effect of pharmacologic doses of DACA on radiotracer kinetics.

PATIENTS AND METHODS: [¹¹C]DACA (at 1/1,000 phase I starting dose) was administered to 24 patients with advanced cancer (pre–phase I) or during a phase I trial of DACA in five patients. Positron emission tomography (PET) was performed to assess pharmacokinetics and tumor blood flow. Plasma samples were analyzed for metabolite profile of [¹¹C]DACA.

RESULTS: There was rapid systemic clearance of [¹¹C]DACA over 60 minutes (1.57 and 1.46 L·min^-1·m^-2in pre–phase I and phase I studies, respectively) with the production of several radiolabeled plasma metabolites. Tumor, brain, myocardium, vertebra, spleen, liver, lung, and kidneys showed appreciable uptake of ¹¹C radioactivity. The area under the time-versus-radioactivity curves (AUC) showed the highest variability in tumors. Of interest to potential toxicity, maximum radiotracer concentrations (Cmax) in brain and vertebra were low (0.67 and 0.54 m²·mL^-1, respectively) compared with other tissues. A moderate but significant correlation was observed for tumor blood flow with AUC (r = 0.76; P = .02) and standardized uptake value (SUV) at 55 minutes (r = 0.79; P = .01). A decrease in myocardial AUC ( P = .03) and splenic and myocardial SUV ( P = .01 and .004, respectively) was seen in phase I studies. Significantly higher AUC, SUV, and Cmax were observed in tumors in phase I studies.

CONCLUSION: The distribution of [¹¹C]DACA and its radiolabeled metabolites was observed in a variety of tumors and normal tissues. In the presence of unlabeled DACA, pharmacokinetics were altered in myocardium, spleen, and tumors. These data have implications for predicting activity and toxicity of DACA and support the use of PET early in drug development.

This article has been cited by other articles:

				D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens Application of PET/CT in the Development of Novel Anticancer Drugs Oncologist, January 1, 2008; 13(1): 25 - 38. [Abstract] [Full Text] [PDF]

				J. Kimmelman Ethics at Phase 0: Clarifying the Issues J. Law Med. Ethics, December 1, 2007; 35(4): 727 - 733. [PDF]

				W.-A. Hsueh, A. L. Kesner, A. Gangloff, M. D. Pegram, M. Beryt, J. Czernin, M. E. Phelps, and D. H.S. Silverman Predicting Chemotherapy Response to Paclitaxel with 18F-Fluoropaclitaxel and PET J. Nucl. Med., December 1, 2006; 47(12): 1995 - 1999. [Abstract] [Full Text] [PDF]

				R. Weissleder Molecular imaging in cancer. Science, May 26, 2006; 312(5777): 1168 - 1171. [Abstract] [Full Text] [PDF]

				P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, and J. Zweit Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst, May 3, 2006; 98(9): 580 - 598. [Abstract] [Full Text] [PDF]

				A Saleem Potential of PET in oncology and radiotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 6 - 16. [Full Text] [PDF]

				A. Saleem, G. D. Brown, F. Brady, E. O. Aboagye, S. Osman, S. K. Luthra, A. S. O. Ranicar, C. S. Brock, M. F. G. Stevens, E. Newlands, et al. Metabolic Activation of Temozolomide Measured in Vivo Using Positron Emission Tomography Cancer Res., May 15, 2003; 63(10): 2409 - 2415. [Abstract] [Full Text] [PDF]

				P. Wells, E. Aboagye, R. N. Gunn, S. Osman, A. V. Boddy, G. A. Taylor, I. Rafi, A. N. Hughes, A. H. Calvert, P. M. Price, et al. 2-[11C]Thymidine Positron Emission Tomography as an Indicator of Thymidylate Synthase Inhibition in Patients Treated With AG337 J Natl Cancer Inst, May 7, 2003; 95(9): 675 - 682. [Abstract] [Full Text] [PDF]

				D.J. Propper, J. de Bono, A. Saleem, S. Ellard, E. Flanagan, J. Paul, T.S. Ganesan, D.C. Talbot, E.O. Aboagye, P. Price, et al. Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000 J. Clin. Oncol., January 15, 2003; 21(2): 203 - 210. [Abstract] [Full Text] [PDF]